Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prostatic Artery Embolization Using Histoacryl as a Novel Embolizing Agent for Treatment of BPH
Sponsor: Assiut University
Summary
Benign prostatic hyperplasia (BPH) is a common non-cancerous enlargement of the prostate gland in aging men that causes bothersome lower urinary tract symptoms (LUTS), including frequent urination, weak urinary stream, and difficulty emptying the bladder. Prostatic artery embolization (PAE) is a minimally invasive, image-guided catheter procedure that blocks blood flow to the prostate, leading to gland shrinkage and symptom relief. While traditional PAE utilizes particulate agents, N-butyl cyanoacrylate (NBCA / Histoacryl) glue is a liquid embolic material that may offer advantages such as shorter procedural duration, lower radiation exposure, and permanent vascular occlusion. The purpose of this prospective, single-arm study is to evaluate the feasibility, safety, and clinical efficacy of using Histoacryl glue mixed with Lipiodol (1:8 dilution ratio) during prostatic artery embolization in men with symptomatic BPH who have failed or cannot tolerate medical therapy. All enrolled participants will undergo PAE with the Histoacryl glue mixture. Participants will be monitored for procedural safety and followed up at 1 month and 3 months post-procedure. Follow-up assessments include urinary symptom improvement using the International Prostate Symptom Score (IPSS), quality of life (QoL) ratings, post-void residual urine volume, prostate-specific antigen (PSA) levels, pelvic imaging to measure prostate volume reduction, and monitoring for any procedure-related complications.
Key Details
Gender
MALE
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-11
Completion Date
2027-12
Last Updated
2026-10-29
Healthy Volunteers
No
Interventions
Prostatic Artery Embolization with N-butyl Cyanoacrylate
Participants undergo transcatheter prostatic artery embolization (PAE) performed in an angiography suite. Vascular access is secured using a 5 Fr vascular sheath and diagnostic catheter (5 Fr cobra), followed by superselective catheterization of the prostatic arteries using a 2.0-2.7 Fr microcatheter with a hydrophilic microwire. After flushing the microcatheter with a non-ionic 5% glucose solution to prevent premature polymerization, embolization is performed by injecting an N-butyl cyanoacrylate (NBCA / Histoacryl) and Lipiodol mixture at an optimized 1:8 dilution ratio under real-time fluoroscopic guidance until complete vascular stasis is achieved.